Celcuity Stock (NASDAQ:CELC)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$90.08

52W Range

$44.42 - $151.02

50D Avg

$94.03

200D Avg

$106.15

Market Cap

$4.17B

Avg Vol (3M)

$1.23M

Beta

0.16

Div Yield

CELC Company Profile

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

155

IPO Date

Sep 19, 2017

Website

CELC Performance

CELC Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-172.19M	$-113.27M	$-66.23M
Net Income	$-177.04M	$-111.78M	$-63.78M
EBITDA	$-172.19M	$-101.37M	$-58.31M
Basic EPS	$-3.78	$-2.83	$-2.69
Diluted EPS	$-3.78	$-2.83	$-2.69

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 13, 26 | 4:30 PM

Q1 26May 14, 26 | 4:30 PM

Q4 25Mar 25, 26 | 4:30 PM

Peer Comparison

Ticker	Company
CGON	CG Oncology Inc.
XENE	Xenon Pharmaceuticals Inc.
APGE	Apogee Therapeutics, Inc.
IRON	Disc Medicine, Inc.
ZLAB	Zai Lab Limited
AAPG	Ascentage Pharma Group International
TVTX	Travere Therapeutics, Inc.
RARE	Ultragenyx Pharmaceutical Inc.
LEGN	Legend Biotech Corporation